FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Koji Harada

Research Profile

Disorders

Living Beings

Chemicals & Drugs

Anatomy

Procedures

Xenograft Model Antitumor Assays

Phenomena

Blotting, Western

Physiology

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Tarannum Ferdous; Koji Harada; Toyoko Harada; Takanori Kin; Yoshiya Ueyama
Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells.
Toyoko Harada; Koji Harada; Yoshiya Ueyama
The enhancement of tumor radioresponse by combined treatment with cepharanthine is accompanied by the inhibition of DNA damage repair and the induction of apoptosis in oral squamous cell carcinoma.
Takamitsu Mano; Koji Harada; Kunio Ishikawa; Hirotsugu Umeda; Yoshiya Ueyama
Comparison of apatite-coated titanium prepared by blast coating and flame spray methods--evaluation using simulated body fluid and initial histological study.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Koji Harada (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Tarannum Ferdous; Koji Harada; Toyoko Harada; Takanori Kin; Yoshiya Ueyama
Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells.
International journal of oncology 2013;43(1):271-9.
2012: Toyoko Harada; Koji Harada; Yoshiya Ueyama
The enhancement of tumor radioresponse by combined treatment with cepharanthine is accompanied by the inhibition of DNA damage repair and the induction of apoptosis in oral squamous cell carcinoma.
International journal of oncology 2012;41(2):565-72.
2011: Takamitsu Mano; Koji Harada; Kunio Ishikawa; Hirotsugu Umeda; Yoshiya Ueyama
Comparison of apatite-coated titanium prepared by blast coating and flame spray methods--evaluation using simulated body fluid and initial histological study.
Dental materials journal 2011;30(4):431-7.
2010: Koji Harada; Yasutaka Itashiki; Takanori Takenawa; Yoshiya Ueyama
Effects of lentinan alone and in combination with fluoropyrimidine anticancer agent on growth of human oral squamous cell carcinoma in vitro and in vivo.
International journal of oncology 2010;37(3):623-31.
2009: Koji Harada; Tarannum Ferdous; Yasutaka Itashiki; Michiyo Takii; Takamichi Mano; Yoshihide Mori; Yoshiya Ueyama
Cepharanthine inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing expression of vascular endothelial growth factor and interleukin-8.
International journal of oncology 2009;35(5):1025-35.
2009: Koji Harada; Tarannum Ferdous; Yasutaka Itashiki; Michiyo Takii; Takamichi Mano; Yoshihide Mori; Yoshiya Ueyama
Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Anticancer research 2009;29(4):1263-70.
2008: Koji Harada; Mitsunobu Sato; Yoshiya Ueyama; Masaru Nagayama; Hiroyuki Hamakawa; Shunichirou Nagahata; Yasuro Yoshimura; Tokio Osaki; Kazuo Ryoke
Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma.
Anti-cancer drugs 2008;19(1):85-90.
2007: Koji Harada; Tarannum Ferdous; Hideo Yoshida
Investigation of optimal schedule of concurrent radiotherapy with S-1 for oral squamous cell carcinoma.
Oncology reports 2007;18(5):1077-83.
2007: Koji Harada; Tetsuya Tamatani; Takashi Bando; Hideo Yoshida
[A case of oral squamous cell carcinoma responding to S-1].
Gan to kagaku ryoho. Cancer & chemotherapy 2007;34(9):1455-8.
2007: Yasutaka Itashiki; Koji Harada; Tarannum Ferdous; Hideo Yoshida
Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Anticancer research 2007;27(4B):2365-75.
2007: Koji Harada; Yuichiro Kawashima; Hideo Yoshida; Mitsunobu Sato
S-1 inhibits tumorigenicity and angiogenesis of human oral squamous cell carcinoma cells by suppressing expression of phosphorylated Akt, vascular endothelial growth factor and fibroblast growth factor-2.
International journal of oncology 2007;30(2):365-74.
2006: Koji Harada; Yuichiro Kawashima; Hideo Yoshida; Mitsunobu Sato
Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1.
Oncology reports 2006;15(6):1417-23.
2006: Koji Harada; Yuichiro Kawashima; Hideo Yoshida; Mitsunobu Sato
High expression of Jun activation domain-binding protein 1 (Jab1) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation.
Anticancer research 2006;26(2B):1615-9.
2005: Koji Harada; Hideo Yoshida; Mitsunobu Sato
Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
International journal of oncology 2005;27(6):1489-97.
2005: Koji Harada; Hideo Yoshida; Mitsunobu Sato
Basic investigation on the development of molecular targeting therapy against cyclin-dependent kinase inhibitor p27Kip1 in head and neck cancer cells.
International journal of oncology 2005;27(3):627-35.
2005: Koji Harada; Shin-ichi Kawaguchi; Yuichiro Kawashima; Hideo Yoshida; Mitsunobu Sato
S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB.
Cancer letters 2005;226(2):161-168.
2005: Koji Harada; Yuichiro Kawashima; Yasutaka Itashiki; Hideo Yoshida; Mitsunobu Sato
Down-regulation of S-phase kinase associated protein 2 (Skp2) induces apoptosis in oral cancer cells.
Oral oncology 2005;41(6):623-30.
2005: Koji Harada; Shin-ichi Kawaguchi; Yuichiro Kawashima; Yasutaka Itashiki; Hideo Yoshida; Mitsunobu Sato
High expression of S-phase kinase-associated protein 2 (Skp2) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation.
Anticancer research 2005;25(3c):2471-5.
2005: Koji Harada; Shin-ichi Kawaguchi; Tomitaro Onoue; Yuichiro Kawashima; Hideo Yoshida; Mitsunobu Sato
High antitumor activity using intratumoral injection of plasmid DNA with mutant-type p27Kip1 gene following in vivo electroporation.
Oncology reports 2005;13(2):201-6.
2004: Koji Harada; Shin-ichi Kawaguchi; Tomitaro Onoue; Hideo Yoshida; Mitsunobu Sato
Enhancement of apoptosis in salivary gland cancer cells by the combination of oral fluoropyrimidine anticancer agent (S-1) and radiation.
International journal of oncology 2004;25(4):905-11.
2004: Koji Harada; Shin-ichi Kawaguchi; Tomitaro Onoue; Hideo Yoshida; Mitsunobu Sato
Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells.
Oral oncology 2004;40(7):713-9.
2004: Koji Harada; Shin-ichi Kawaguchi; Tomitaro Onoue; Hideo Yoshida; Mitsunobu Sato
Characteristics of antitumor activity of mutant type p27Kip1 gene in an oral cancer cell line.
Oral oncology 2004;40(7):679-87.
2004: Koji Harada; Shin-ichi Kawaguchi; Onoue Tomitaro; Hideo Yoshida; Mitsunobu Sato
Overexpression of iNOS gene suppresses the tumorigenicity and metastasis of oral cancer cells.
In vivo (Athens, Greece) 2004;18(4):449-55.
2004: Masayuki Azuma; Koji Harada; Tetsuya Tamatani; Katsumi Motegi; Yuki Ashida; Mitsunobu Sato
Potentiation of induction of apoptosis by sequential treatment with cisplatin followed by 5-fluorouracil in human oral cancer cells.
International journal of oncology 2004;24(6):1449-55.
2004: Tetsuya Tamatani; Masayuki Azuma; Yuki Ashida; Katsumi Motegi; Rina Takashima; Koji Harada; Shin-ichi Kawaguchi; Mitsunobu Sato
Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8.
International journal of cancer. Journal international du cancer 2004;108(6):912-21.
2003: Shin-ichi Kawaguchi; Koji Harada; Hideo Yoshida; Mitsunobu Sato
Overexpression of tuberous sclerosis complex 2 exerts antitumor effect on oral cancer cell lines.
Oral oncology 2003;39(8):836-41.
2003: Koji Harada; Shin-ichi Kawaguchi; Hideo Yoshida; Mitsunobu Sato
Effect of p27Kip1 on the ability of invasion and metastasis of an oral cancer cell line.
Oncology reports 2003;10(3):527-32.
2003: Masayuki Azuma; Tetsuya Tamatani; Yuki Ashida; R Takashima; Koji Harada; Mitsunobu Sato
Cisplatin induces apoptosis in oral squamous carcinoma cells by the mitochondria-mediated but not the NF-kappaB-suppressed pathway.
Oral oncology 2003;39(3):282-9.
2003: Koji Harada; Shin Yamamoto; Shin-ichi Kawaguchi; Hideo Yoshida; Mitsunobu Sato
Cepharanthine exerts antitumor activity on oral squamous cell carcinoma cell lines by induction of p27Kip1.
Anticancer research 2003;23(2B):1441-8.
2002: Koji Harada; Mohammad Hoque; Takashi Bando; Hideo Yoshida; Mitsunobu Sato
Overexpression of p27(Kip1) induces growth arrest and apoptosis in an oral cancer cell line.
Oral oncology 2002;38(7):730-6.
2002: Koji Harada; Hideo Yoshida; Mitsunobu Sato
Low p27Kip1 expression is associated with poor prognosis in oral squamous cell carcinoma.
Anticancer research 2002;22(5):2985-9.
2002: Mohammad Hoque; Hitoshi Kawamata; Koh-ichi Nakashiro; Fumie Omotehara; Satoshi Hino; Daisuke Uchida; Koji Harada; Nasima-Mila Begum; Hideo Yoshida; Mitsunobu Sato; Takahiro Fujimori
Dysfunction of the p53 tumor suppressor pathway in head and neck cancer.
International journal of oncology 2002;21(1):119-26.
2001: Koji Harada; Takashi Bando; Hideo Yoshida; Mitsunobu Sato
Characteristics of antitumour activity of cepharanthin against a human adenosquamous cell carcinoma cell line.
Oral oncology 2001;37(8):643-51.
2001: Katsumi Motegi; Masayuki Azuma; Keiko Aota; Tsuyoshi Yamashita; Tetsuya Tamatani; Koji Harada; Hideo Yoshida; Mitsunobu Sato
Effect of a mutant form of IkappaB-alpha on 5-fluorouracil-induced apoptosis in transformed human salivary gland cells.
Oral oncology 2001;37(2):185-92.
2000: Masayuki Azuma; Keiko Aota; Tetsuya Tamatani; Katsumi Motegi; Tsuyoshi Yamashita; Koji Harada; Yoshio Hayashi; Mitsunobu Sato
Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor kappaBalpha complementary DNA into immortalized human salivary gland acinar cells. Prevention of the destruction of the acinar structure in Sjögren's syndrome salivary glands.
Arthritis and rheumatism 2000;43(8):1756-67.
1997: Mitsunobu Sato; Hitoshi Kawamata; Koji Harada; Koh-ichi Nakashiro; Y Ikeda; H Gohda; Hideo Yoshida; T Nishida; K Ono; M Kinoshita; M Adachi
Induction of cyclin-dependent kinase inhibitor, p21WAF1, by treatment with 3,4-dihydro-6-[4-(3,4)-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinoline (vesnarinone) in a human salivary cancer cell line with mutant p53 gene.
Cancer letters 1997;112(2):181-9.
1997: Hitoshi Kawamata; Koh-ichi Nakashiro; Daisuke Uchida; Koji Harada; Hideo Yoshida; Mitsunobu Sato
Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines.
International journal of cancer. Journal international du cancer 1997;70(1):120-7.
1995: M Sato; Koji Harada; T Bando; T Shirakami; Koh-ichi Nakashiro; H Yoshida; S Nakai; K Kawai; M Adachi
Characteristics of antitumor activity of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]- 2(1H)-quinolinone (vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in athymic nude mice.
Cancer letters 1995;91(1):1-9.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.